These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25193492)

  • 1. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
    Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
    Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
    Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
    Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
    Casolaro A; Golay J; Albanese C; Ceruti R; Patton V; Cribioli S; Pezzoni A; Losa M; Texido G; Giussani U; Marchesi F; Amboldi N; Valsasina B; Bungaro S; Cazzaniga G; Rambaldi A; Introna M; Pesenti E; Alzani R
    PLoS One; 2013; 8(3):e58424. PubMed ID: 23520509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
    Hartsink-Segers SA; Exalto C; Allen M; Williamson D; Clifford SC; Horstmann M; Caron HN; Pieters R; Den Boer ML
    Haematologica; 2013 Oct; 98(10):1539-46. PubMed ID: 23753023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells.
    Kudo M; Zalles N; Distefano R; Nigita G; Veneziano D; Gasparini P; Croce CM
    Cell Death Differ; 2022 Feb; 29(2):407-419. PubMed ID: 34561554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
    Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
    Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
    Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
    Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
    Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
    J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
    Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
    Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
    Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
    Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional genome screen for therapeutic targets of osteosarcoma.
    Yamaguchi U; Honda K; Satow R; Kobayashi E; Nakayama R; Ichikawa H; Shoji A; Shitashige M; Masuda M; Kawai A; Chuman H; Iwamoto Y; Hirohashi S; Yamada T
    Cancer Sci; 2009 Dec; 100(12):2268-74. PubMed ID: 19725836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 as a potential therapeutic target for osteosarcoma.
    Cheng L; Wang C; Jing J
    Curr Pharm Des; 2015; 21(10):1347-50. PubMed ID: 25345614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.
    Gao J; Huang W; Zhao S; Wang R; Wang Z; Ye J; Lin L; Cai W; Mi Y
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23590. PubMed ID: 38037286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition.
    Yen CC; Hsiao CD; Chen WM; Wen YS; Lin YC; Chang TW; Yao FY; Hung SC; Wang JY; Chiu JH; Wang HW; Lin CH; Chen TH; Chen PC; Liu CL; Tzeng CH; Fletcher JA
    Oncotarget; 2014 Feb; 5(3):716-25. PubMed ID: 24566468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.